USANA Health Sciences (NYSE:USNA) Stock Moved Down to “Strong Sell” by Zacks Research

Zacks Research downgraded shares of USANA Health Sciences (NYSE:USNA) from a hold rating to a strong sell rating in a research report sent to investors on Wednesday,Zacks reports.

Other equities analysts have also issued research reports about the company. Weiss Ratings restated a “sell (d)” rating on shares of USANA Health Sciences in a research note on Monday, September 21st. Wall Street Zen downgraded USANA Health Sciences from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Two equities research analysts have rated the stock with a Sell rating. According to MarketBeat, the stock presently has a consensus rating of “Sell”.

USANA Health Sciences Trading Down 3.3%

Shares of USANA Health Sciences stock opened at $13.86 on Wednesday. USANA Health Sciences has a 12-month low of $12.57 and a 12-month high of $23.59. The firm has a market capitalization of $256.05 million, a price-to-earnings ratio of -12.05, a PEG ratio of 2.17 and a beta of 0.66. The firm’s 50 day simple moving average is $14.61 and its two-hundred day simple moving average is $17.99.

USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.22). The company had revenue of $205.89 million during the quarter, compared to analysts’ expectations of $217.42 million. USANA Health Sciences had a positive return on equity of 3.56% and a negative net margin of 2.34%. On average, sell-side analysts predict that USANA Health Sciences will post 0.55 EPS for the current fiscal year.

Institutional Trading of USANA Health Sciences

Several institutional investors and hedge funds have recently bought and sold shares of USNA. Versant Capital Management Inc boosted its holdings in USANA Health Sciences by 1,472.3% in the second quarter. Versant Capital Management Inc now owns 1,588 shares of the company’s stock valued at $34,000 after purchasing an additional 1,487 shares during the last quarter. GAMMA Investing LLC grew its position in USANA Health Sciences by 689.4% during the 3rd quarter. GAMMA Investing LLC now owns 2,763 shares of the company’s stock worth $40,000 after purchasing an additional 2,413 shares during the period. State of Wyoming purchased a new position in shares of USANA Health Sciences during the 1st quarter valued at about $57,000. GSA Capital Partners LLP purchased a new position in shares of USANA Health Sciences during the 2nd quarter valued at about $250,000. Finally, DGS Capital Management LLC purchased a new position in shares of USANA Health Sciences during the 1st quarter valued at about $208,000. 54.25% of the stock is currently owned by institutional investors and hedge funds.

More USANA Health Sciences News

Here are the key news stories impacting USANA Health Sciences this week:

• Positive Sentiment: Sidoti slightly raised its Q4 2026 EPS estimate to $0.12 from $0.11, a modest offset to its broader forecast reductions. USANA analyst estimates
• Negative Sentiment: USANA’s Q3 2026 results missed expectations: the company reported a loss of $0.11 per share versus consensus earnings of $0.11, while revenue of $205.9 million fell short of the $217.4 million estimate. Sales declined 4% year over year. USANA Q3 results and outlook
• Negative Sentiment: The company lowered its FY2026 outlook, now projecting net sales approaching $900 million and adjusted EBITDA of approximately $77 million. The reduced guidance suggests weaker near-term business performance. USANA updates its outlook
• Negative Sentiment: Sidoti lowered its FY2027 EPS forecast to $1.59 from $1.77 and cut estimates for Q1, Q2, and Q3 2027, indicating less confidence in earnings growth beyond 2026. USANA analyst estimates

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops and sells nutritional supplements, healthy foods and personal-care products through a direct-selling business model. Its product portfolio includes vitamins and mineral supplements, meal-replacement and snack products, sports nutrition offerings, and skincare products marketed under the USANA and related brands.

Founded in 1992 by microbiologist and immunologist Myron W. Wentz, the company is headquartered in Salt Lake City, Utah. USANA distributes its products through a network of independent associates and preferred customers rather than primarily through traditional retail channels.

The company serves customers in markets across the Americas, Asia-Pacific and Europe, with a significant presence in countries including the United States, Canada, Australia, New Zealand, China, Hong Kong, Japan, South Korea, the Philippines, Singapore, Malaysia and Thailand.